(Updates)

** Vera Therapeutics' shares fall 2.8% to $46.04 after the bell

** VERA

unveils

plans to sell $300 mln worth of shares in a proposed public offering

** J.P. Morgan, Goldman Sachs, Evercore ISI and Cantor are the joint book-running managers for the proposed offering

** VERA stock closed up 15.2% at $47.34 on Monday

** Co has 54.8 mln outstanding shares giving it a market capitalization of $2.60 bln - LSEG data

** On Saturday, Vera reported additional data from a mid-stage study testing its kidney disease drug, atacicept, as a potential treatment for IgA nephropathy

** IgA nephropathy causes a protein called immunoglobulin A to build up in the kidney

** At week 96, atacicept helped in reducing excess levels of a protein in urine and stabilizing kidney function levels, compared to placebo - VERA

** VERA said it will submit results from late-stage study of atacicept in Q2 2025

** As of last close, VERA stock has more than tripled YTD

(Reporting by Christy Santhosh and Arasu Kannagi Basil in Bengaluru)

((Christy.Santhosh@thomsonreuters.com))